As the landscape of obesity medicine undergoes a seismic shift with the widespread adoption of glucagon-like peptide-1 (GLP-1) receptor agonists, the field of plastic and reconstructive surgery is facing a new set of clinical challenges. A groundbreaking study published in the April issue of Plastic and Reconstructive Surgery®, the official journal of the American Society of Plastic Surgeons (ASPS), has provided the first detailed look at how these popular weight-loss drugs—such as semaglutide and tirzepatide—interact with the body’s healing processes following abdominal body contouring surgery.
The study, titled "Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis," suggests that while these medications do not necessarily spike the risk of catastrophic surgical failure, they do introduce a "complex and nuanced" influence on how patients heal.
Main Facts: A Paradigm Shift in Patient Care
Body contouring, specifically panniculectomy—a procedure to remove redundant, hanging skin and fat from the lower abdomen—has become a standard of care for patients who have achieved massive weight loss. Historically, surgeons focused on stabilizing a patient’s BMI and nutritional status before operating. Today, however, a significant percentage of these patients arrive in the operating room already on a regimen of GLP-1 receptor agonists (GLP1ra).
The core finding of the research is that GLP-1 usage is associated with a "mixed bag" of outcomes. While these patients are not at a higher risk of major surgical complications like systemic infection or the need for emergency rehospitalization, they exhibit a distinct physiological response at the site of the incision. Specifically, patients on these medications showed a statistically significant increase in delayed wound healing but a surprising, marked decrease in the incidence of seromas—the painful, fluid-filled pockets that often plague post-surgical recovery.
Chronology: A Decade of Data in West Virginia
To understand the impact of these drugs, lead author Dr. Zachary Andrew Koenig and his team at the West Virginia University School of Medicine conducted a retrospective analysis covering a decade of surgical data, from 2013 to 2023.
- 2013–2018: During the early years of the study, the use of GLP-1 agonists among panniculectomy patients was relatively sporadic, reflecting the drug’s primary use as a targeted therapy for type 2 diabetes.
- 2019–2021: As GLP-1 medications began to be marketed and prescribed more broadly for weight management, the researchers observed a sharp, linear increase in the number of patients undergoing body contouring who were simultaneously taking these agents.
- 2022–2023: By the end of the study period, the prevalence of GLP-1 usage among the surgical cohort reached 21.7%. This rapid surge made the West Virginia University medical center an ideal "living laboratory," given that West Virginia currently reports some of the highest rates of GLP-1 prescriptions in the United States.
- The Analysis Phase: Researchers filtered out patients undergoing concurrent bariatric or hernia repair surgeries to ensure the data specifically reflected the effects of the medication on the panniculectomy site itself, rather than the secondary effects of more invasive abdominal surgeries.
Supporting Data: Dissecting the Complication Profiles
The study’s data highlights a clear divergence in how GLP-1 users recover compared to their counterparts who are not taking the medication.
The Wound Healing Paradox
The most critical finding involves wound integrity. Patients on GLP-1 therapy experienced a 18.5% rate of delayed wound healing, compared to just 7.5% in the non-GLP-1 group. This suggests that the medications may interfere with the body’s natural inflammatory response or collagen deposition phases required for robust tissue repair.
The Seroma Advantage
Conversely, the data offered a positive surprise regarding seromas. Fluid buildup under the skin (seroma) is a common, often recurring complication after skin excision. The study found that GLP-1 users had a significantly lower rate of seroma at 4.9%, compared to 14.0% in the control group. The mechanism behind this remains speculative; however, some clinicians hypothesize that the medication’s metabolic effects on adipose tissue or systemic inflammatory modulation might contribute to this reduction in fluid collection.
Parity in Major Risks
Crucially, for patients and surgeons concerned about safety, the study found no significant differences between the two groups regarding:
- Wound Dehiscence: The rate of surgical wounds splitting open remained comparable.
- Infection: Rates of surgical site infections were statistically similar.
- Rehospitalization: The necessity for emergency care post-discharge did not differ significantly.
Official Responses and Clinical Perspectives
Dr. Zachary Andrew Koenig, in discussing the findings, emphasized that the integration of GLP-1 drugs into plastic surgery is no longer a "future consideration"—it is an immediate clinical reality.
"Our findings suggest that while GLP1ra therapy does not appear to increase major surgical risk, it may affect specific aspects of healing that warrant proactive management," Dr. Koenig stated. He stresses that the "unique mechanisms" at play are not yet fully understood, and the medical community must move away from a "one-size-fits-all" approach to preoperative counseling.
The study underscores the necessity for surgeons to engage in a more nuanced dialogue with patients. If a patient is on a GLP-1 agonist, the surgeon must now weigh the benefit of the medication’s weight-loss properties against the potential for delayed wound closure. This may involve closer monitoring in the immediate post-operative window or more frequent office visits to ensure the incision is knitting correctly.
Implications: The Need for Standardized Guidelines
The medical community is currently at a crossroads. As these drugs become ubiquitous, the lack of formal, evidence-based guidelines regarding their "perioperative management" (whether to pause or continue the medication before surgery) is a glaring gap in current surgical protocols.
Implications for Future Practice:
- Patient Counseling: Surgeons should explicitly discuss the risk of delayed wound healing with patients who are on GLP-1 therapy, ensuring they understand that "delayed healing" does not equate to "surgical failure," but does require strict adherence to post-operative wound care instructions.
- Multidisciplinary Cooperation: There is a growing need for closer collaboration between the prescribing endocrinologist or primary care physician and the plastic surgeon to determine if a "washout period" (stopping the medication before surgery) is necessary or beneficial.
- Future Research: The study by Dr. Koenig and his colleagues serves as a foundational piece of evidence, but it is just the beginning. Future prospective, randomized trials are required to determine if dosage adjustments or specific timing of medication cessation could mitigate the risk of delayed healing while retaining the benefits of metabolic optimization.
- Beyond Aesthetics: As panniculectomy is often performed for both functional (e.g., resolving chronic skin infections, rashes, and back pain) and aesthetic reasons, understanding these risks is essential for insurance coverage and clinical outcomes in a population that often has complex metabolic comorbidities.
The findings from the West Virginia University team provide a valuable, data-driven framework for surgeons navigating the new era of "medicated surgery." As the clinical landscape continues to evolve, the focus will undoubtedly shift toward balancing the profound metabolic benefits of GLP-1 agonists with the technical realities of wound management. For now, the takeaway is clear: the patient on GLP-1 therapy is a unique surgical candidate who requires a customized, vigilant approach to recovery.
About the Research Source
Plastic and Reconstructive Surgery® is the official journal of the American Society of Plastic Surgeons. For more information on the study or to access the full report, practitioners and researchers can refer to the publication of record, which remains committed to advancing the science of plastic surgery through rigorous, evidence-based clinical investigation.
DOI: 10.1097/PRS.0000000000012405
About the Author
